Novel Ansamycin Antibiotics to combat AntiMicrobial Resistance

新型安沙霉素抗生素可对抗抗菌素耐药性

• 批准号: 91699
• 金额: $ 9.21万
• 依托单位: DEMURIS LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=91699
• 关键词: Novel; Ansamycin; Antibiotics; combat; AntiMicrobial

As the death toll from the COVID-19 pandemic passes 1 million and healthcare systems around the globe are struggling to cope there is another problem on the horizon, of Antimicrobial Resistance (AMR). The COVID-19 pandemic has increased the usage of antibiotics due to being administered to patients for the prevention of secondary bacterial infections. The pandemic has highlighted how unprepared the world is for significant healthcare disruption and the need for investment in medicines to combat these disruptions.AMR was already a global problem, each year the US Centers for Disease Control and Prevention estimates that 2.8 million Americans acquire serious infections caused by antibiotic-resistant bacteria, and 35,000 of them die as a result.AMR is a growing problem with vast societal and economic consequences. Pathogenic bacteria are becoming increasingly resistant to antibiotics and some strains are now resistant to all clinically used antibiotics. At the same time, the rate of discovery and deployment of new antibiotics has declined. Unfortunately, most major pharmaceutical companies have curtailed their antimicrobial and anti-infective discovery programs in favour of more profitable, lower-risk programs.Demuris is a SME that through screening a large collection of actinomycete bacteria has identified a novel ansamycin antibiotic. It has good potency towards multi-drug-resistant Gram-negative bacteria ,which are greatest threat to the public. This project will enable the production of the compound at a scale which will enable the evaluation of any human toxicity and the potency towards a panel of hospital pathogens.

随着 COVID-19 大流行的死亡人数超过 100 万，全球医疗保健系统都在努力应对，另一个问题即将出现，即抗菌素耐药性 (AMR)。由于给患者施用抗生素来预防继发细菌感染，COVID-19 大流行增加了抗生素的使用。这场大流行凸显出世界对严重的医疗保健中断毫无准备，也需要投资药物来应对这些中断。抗菌素耐药性已经是一个全球性问题，美国疾病控制和预防中心估计，每年有 280 万美国人受到抗生素耐药性细菌引起的严重感染，其中 35,000 人因此死亡。抗菌素耐药性是一个日益严重的问题，带来了巨大的社会和经济后果。致病菌对抗生素的耐药性越来越强，一些菌株现在对所有临床使用的抗生素都具有耐药性。与此同时，新抗生素的发现和部署速度有所下降。不幸的是，大多数主要制药公司都削减了抗菌和抗感染发现项目，转而支持利润更高、风险更低的项目。Demuris 是一家中小型企业，通过筛选大量放线菌，发现了一种新型安莎霉素抗生素。它对对公众构成最大威胁的多重耐药革兰氏阴性菌具有良好的效力。该项目将使该化合物的生产规模能够评估任何人体毒性和对一组医院病原体的效力。